News
Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback